budesonide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   17 Trials   17 Trials   3666 News 


«12...1920212223242526272829...4243»
  • ||||||||||  budesonide / Generic mfg., nitazoxanide / Generic mfg.
    Journal:  Nitazoxanide against COVID-19 in three explorative scenarios. (Pubmed Central) -  Oct 28, 2020   
    Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success. Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.
  • ||||||||||  budesonide / Generic mfg.
    Trial completion date, Trial primary completion date:  Budesonide in Patients With Immune Mediated Enteropathies (clinicaltrials.gov) -  Oct 19, 2020   
    P4,  N=20, Recruiting, 
    A serial assessment of an individual cat's change in NT-proBNP might be clinically useful for judging risk for volume expansion. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, Bevespi Aerosphere (formoterol/glycopyrrolate) / AstraZeneca
    [VIRTUAL] A SCINTIGRAPHY STUDY OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE IN PATIENTS WITH COPD () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_2652;    
    P1
    These results indicate that doses of BGF 320/18/9.6 µg were deposited homogeneously throughout the entire lung of patients with moderate-to-very severe COPD, across disease severities, generally comparable to BGF deposition in prior studies with healthy volunteers. CLINICAL IMPLICATIONS: BGF MDI was efficiently deposited in both the central and peripheral regions of the lungs of patients with moderate-to-very severe COPD.
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis
    [VIRTUAL] MANAGEMENT OF A CASE OF UNCONTROLLED BRONCHIAL ASTHMA () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_1082;    
    INTRODUCTION: Inadequate treatments or comorbid conditions are known to be frequently encountered factors perpetuating poor asthma control.1 Our case reports an undiagnosed comorbid depression as cause of persistent uncontrolled asthma.CASE PRESENTATION: A 58 years old Caucasian male, non smoker, with late onset allergic asthma was referred to our pulmonary rehabilitation clinic because of deconditioning, wheezing and recurrent asthma exacerbations despite treatment with budesonide-formoterol 200/6 mcg b.i.d., montelukast 10 mg q.i.d...Treatment with Omalizumab failed to achieve clinical improvement and oral corticosteroid sparing...Prednisone could be completely tapered off over 4 weeks... Therefore, we strongly support the view that the multidisciplinary evaluation of comorbid conditions is essential in patients with uncontrolled asthma.
  • ||||||||||  budesonide / Generic mfg.
    Clinical, Journal:  General Practitioner Use of Generically Substitutable Inhaler Devices and the Impact of Training on Device Mastery and Maintenance of Correct Inhaler Technique. (Pubmed Central) -  Oct 11, 2020   
    This study demonstrates that GPs are able to equally demonstrate correct use of the Turbuhaler and Spiromax devices, even though most had not received training on a Spiromax device prior to this study. The significance of being able to demonstrate correct technique on these two devices equally has ramifications on practice and supported generic substitution of inhaler devices at the point of prescribing, as the most impactful measure a GP can take to ensure effective use of inhaled medicine is the correct demonstration of inhaler technique.
  • ||||||||||  budesonide / Generic mfg.
    Clinical, Review, Journal:  Asthma maintenance and reliever therapy: should this be the standard of care? (Pubmed Central) -  Oct 9, 2020   
    The significance of being able to demonstrate correct technique on these two devices equally has ramifications on practice and supported generic substitution of inhaler devices at the point of prescribing, as the most impactful measure a GP can take to ensure effective use of inhaled medicine is the correct demonstration of inhaler technique. Budesonide/formoterol as a single combination maintenance and reliever inhaler is effective in reducing asthma exacerbation risk, requires a lower maintenance dose of ICS, and results in a simplified approach to asthma management.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Controlled drug release for inflammatory bowel disease (IBD). (Pubmed Central) -  Oct 2, 2020   
    The linear correlation between the predicted and actual values for all the batches of optimization is shown with high correlation coefficient (r-value). Therefore, the designed formulation is promising for ileo-cecal targeted pulsatile drug delivery system in the management of Crohn's disease.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Today's improvement in asthma treatment: role of MART and Easyhaler. (Pubmed Central) -  Sep 30, 2020   
    Easyhaler® more closely demonstrates many expected characteristics: effective, consistent performance regardless of inspiration rate, stability, versatility, with several patient acceptability advantages. Asthma control is enhanced by a strong adherence obtained through the combination in a single inhaler of both maintenance and reliever therapy and the availability of a device as close as possible to the characteristics of the ideal inhaler.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract. (Pubmed Central) -  Sep 27, 2020   
    In vivo studies conducted in a murine model of intestinal mucositis demonstrated that the 16% PF127 BUD formulation was able to resolve the inflammatory injury in the intestinal mucosa. Results demonstrate that fine-tuning of PF127 formulations along with adequate selection of the drug agent, thorough characterization of the dispersions and their interactions with biological interfaces leads to the development of effective controlled drug delivery systems targeted to GI inflammatory diseases.